Matches in SemOpenAlex for { <https://semopenalex.org/work/W2041128703> ?p ?o ?g. }
- W2041128703 endingPage "1384.e3" @default.
- W2041128703 startingPage "1377" @default.
- W2041128703 abstract "Objectives To evaluate the lipid-altering efficacy and safety of ezetimibe monotherapy in young children with heterozygous familial hypercholesterolemia (HeFH) or nonfamilial hypercholesterolemia (nonFH). Study design One hundred thirty-eight children 6-10 years of age with diagnosed HeFH or clinically important nonFH (low-density lipoprotein cholesterol [LDL-C] ≥160 mg/dL [4.1 mmol/L]) were enrolled into a multicenter, 12-week, randomized, double-blind, placebo-controlled study. Following screening/drug washout and a 5-week single-blind placebo-run-in with diet stabilization, subjects were randomized 2:1 to daily ezetimibe 10 mg (n = 93) or placebo (n = 45) for 12 weeks. Lipid-altering efficacy and safety were assessed in all treated patients. Results Overall, mean age was 8.3 years, 57% were girls, 80% were white, mean baseline LDL-C was 228 mg/dL (5.9 mmol/L), and 91% had HeFH. After 12 weeks, ezetimibe significantly reduced LDL-C by 27% after adjustment for placebo (P < .001) and produced significant reductions in total cholesterol (21%), nonhigh-density lipoprotein cholesterol (26%), and apolipoprotein B (20%) (P < .001 for all). LDL-C lowering response in sex, race, baseline lipids, and HeFH/nonFH subgroups was generally consistent with overall study results. Ezetimibe was well tolerated, with a safety profile similar to studies in older children, adolescents, and adults. Conclusions Ezetimibe monotherapy produced clinically relevant reductions in LDL-C and other key lipid variables in young children with primary HeFH or clinically important nonFH, with a favorable safety/tolerability profile. Trial registration ClinicalTrials.gov: NCT00867165. To evaluate the lipid-altering efficacy and safety of ezetimibe monotherapy in young children with heterozygous familial hypercholesterolemia (HeFH) or nonfamilial hypercholesterolemia (nonFH). One hundred thirty-eight children 6-10 years of age with diagnosed HeFH or clinically important nonFH (low-density lipoprotein cholesterol [LDL-C] ≥160 mg/dL [4.1 mmol/L]) were enrolled into a multicenter, 12-week, randomized, double-blind, placebo-controlled study. Following screening/drug washout and a 5-week single-blind placebo-run-in with diet stabilization, subjects were randomized 2:1 to daily ezetimibe 10 mg (n = 93) or placebo (n = 45) for 12 weeks. Lipid-altering efficacy and safety were assessed in all treated patients. Overall, mean age was 8.3 years, 57% were girls, 80% were white, mean baseline LDL-C was 228 mg/dL (5.9 mmol/L), and 91% had HeFH. After 12 weeks, ezetimibe significantly reduced LDL-C by 27% after adjustment for placebo (P < .001) and produced significant reductions in total cholesterol (21%), nonhigh-density lipoprotein cholesterol (26%), and apolipoprotein B (20%) (P < .001 for all). LDL-C lowering response in sex, race, baseline lipids, and HeFH/nonFH subgroups was generally consistent with overall study results. Ezetimibe was well tolerated, with a safety profile similar to studies in older children, adolescents, and adults. Ezetimibe monotherapy produced clinically relevant reductions in LDL-C and other key lipid variables in young children with primary HeFH or clinically important nonFH, with a favorable safety/tolerability profile." @default.
- W2041128703 created "2016-06-24" @default.
- W2041128703 creator A5000311224 @default.
- W2041128703 creator A5004254628 @default.
- W2041128703 creator A5011421448 @default.
- W2041128703 creator A5015239758 @default.
- W2041128703 creator A5027489789 @default.
- W2041128703 creator A5032509000 @default.
- W2041128703 creator A5033051531 @default.
- W2041128703 creator A5034796829 @default.
- W2041128703 creator A5051194824 @default.
- W2041128703 creator A5052364466 @default.
- W2041128703 creator A5070247016 @default.
- W2041128703 creator A5077848934 @default.
- W2041128703 creator A5077859957 @default.
- W2041128703 creator A5078336416 @default.
- W2041128703 date "2015-06-01" @default.
- W2041128703 modified "2023-10-13" @default.
- W2041128703 title "Efficacy and Safety of Ezetimibe Monotherapy in Children with Heterozygous Familial or Nonfamilial Hypercholesterolemia" @default.
- W2041128703 cites W1972661406 @default.
- W2041128703 cites W1973858585 @default.
- W2041128703 cites W1977399475 @default.
- W2041128703 cites W1987507883 @default.
- W2041128703 cites W1992084132 @default.
- W2041128703 cites W1996755250 @default.
- W2041128703 cites W2001375687 @default.
- W2041128703 cites W2004195771 @default.
- W2041128703 cites W2011760617 @default.
- W2041128703 cites W2014242436 @default.
- W2041128703 cites W2015544933 @default.
- W2041128703 cites W2020158846 @default.
- W2041128703 cites W2023857030 @default.
- W2041128703 cites W2023939317 @default.
- W2041128703 cites W2034095303 @default.
- W2041128703 cites W2044713434 @default.
- W2041128703 cites W2049092532 @default.
- W2041128703 cites W2058331732 @default.
- W2041128703 cites W2068581409 @default.
- W2041128703 cites W2071663212 @default.
- W2041128703 cites W2073566803 @default.
- W2041128703 cites W2082449592 @default.
- W2041128703 cites W2090231128 @default.
- W2041128703 cites W2091301513 @default.
- W2041128703 cites W2093260782 @default.
- W2041128703 cites W2104058454 @default.
- W2041128703 cites W2105962383 @default.
- W2041128703 cites W2108277329 @default.
- W2041128703 cites W2120289695 @default.
- W2041128703 cites W2122633654 @default.
- W2041128703 cites W2136257213 @default.
- W2041128703 cites W2136295087 @default.
- W2041128703 cites W2150759389 @default.
- W2041128703 cites W2161453510 @default.
- W2041128703 cites W2165624352 @default.
- W2041128703 cites W2168680123 @default.
- W2041128703 cites W2168876694 @default.
- W2041128703 cites W2943032204 @default.
- W2041128703 doi "https://doi.org/10.1016/j.jpeds.2015.02.043" @default.
- W2041128703 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25841542" @default.
- W2041128703 hasPublicationYear "2015" @default.
- W2041128703 type Work @default.
- W2041128703 sameAs 2041128703 @default.
- W2041128703 citedByCount "57" @default.
- W2041128703 countsByYear W20411287032014 @default.
- W2041128703 countsByYear W20411287032015 @default.
- W2041128703 countsByYear W20411287032016 @default.
- W2041128703 countsByYear W20411287032017 @default.
- W2041128703 countsByYear W20411287032018 @default.
- W2041128703 countsByYear W20411287032019 @default.
- W2041128703 countsByYear W20411287032020 @default.
- W2041128703 countsByYear W20411287032021 @default.
- W2041128703 countsByYear W20411287032022 @default.
- W2041128703 countsByYear W20411287032023 @default.
- W2041128703 crossrefType "journal-article" @default.
- W2041128703 hasAuthorship W2041128703A5000311224 @default.
- W2041128703 hasAuthorship W2041128703A5004254628 @default.
- W2041128703 hasAuthorship W2041128703A5011421448 @default.
- W2041128703 hasAuthorship W2041128703A5015239758 @default.
- W2041128703 hasAuthorship W2041128703A5027489789 @default.
- W2041128703 hasAuthorship W2041128703A5032509000 @default.
- W2041128703 hasAuthorship W2041128703A5033051531 @default.
- W2041128703 hasAuthorship W2041128703A5034796829 @default.
- W2041128703 hasAuthorship W2041128703A5051194824 @default.
- W2041128703 hasAuthorship W2041128703A5052364466 @default.
- W2041128703 hasAuthorship W2041128703A5070247016 @default.
- W2041128703 hasAuthorship W2041128703A5077848934 @default.
- W2041128703 hasAuthorship W2041128703A5077859957 @default.
- W2041128703 hasAuthorship W2041128703A5078336416 @default.
- W2041128703 hasConcept C126322002 @default.
- W2041128703 hasConcept C134018914 @default.
- W2041128703 hasConcept C142724271 @default.
- W2041128703 hasConcept C168563851 @default.
- W2041128703 hasConcept C197934379 @default.
- W2041128703 hasConcept C204787440 @default.
- W2041128703 hasConcept C27081682 @default.
- W2041128703 hasConcept C2778163477 @default.
- W2041128703 hasConcept C2778270857 @default.
- W2041128703 hasConcept C2778375690 @default.